CliffBio
small molecule

FUROSCIX

FUROSEMIDE

Loss of exclusivityApril 2034latest FDA-listed patent expiry
CompanyscPharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameFUROSCIX
Active ingredientFUROSEMIDE
Strength80MG/10ML (8MG/ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalOctober 2022
Marketing statusRX

Listed patents

PatentExpiresType
11433044April 2034use U-3462
9884039April 2034use U-3462
12370168April 2034product
10272064April 2034product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

FUROSCIX patent cliff — loss of exclusivity April 2034 | CliffBio